Institute of Hospital and Health Care Administration, National Yang-Ming University, No.155, Sec. 2, Li-Nong St., Taipei 112, Taiwan.
Eur J Health Econ. 2012 Jun;13(3):347-53. doi: 10.1007/s10198-011-0307-1. Epub 2011 Mar 27.
The purpose of this study was to determine cancer-related medical care costs for long-term cancer care costs of breast, cervical, liver, lung, and colorectal cancer. Data were sourced from Taipei Veterans General Hospital cancer registry and claim data during 1999-2002. Besides, claimed data from National Health Insurance were used to match the comparison group. To estimate lifetime cost (10 years), the whole disease process was divided into initial, continuing, and terminal three phases. The expected lifetime cost of a specific cancer patient was estimated by incorporating the average phase-specific costs with the survival rate and mortality rate. The undiscounted average lifetime costs (10 years) for lung cancer, colorectal cancer, liver cancer, cervical cancer, and breast cancer were NT$448,371 (1USD≒NTD 33), NT$584,985, NT$351,222, NT$511,563, and NT$674,282 (in 2002 NTD), respectively. The aggregate lifetime cost of cancer is useful for health policymaking and clinical decision-making.
本研究旨在确定乳腺癌、宫颈癌、肝癌、肺癌和结直肠癌的长期癌症护理成本的癌症相关医疗费用。数据来源于 1999 年至 2002 年台北荣民总医院癌症登记处和理赔数据。此外，还使用了全民健康保险的理赔数据来匹配对照组。为了估计终身成本（10 年），将整个疾病过程分为初始、持续和终末期三个阶段。特定癌症患者的预期终身成本是通过将各阶段的平均成本与生存率和死亡率相结合来估计的。未贴现的 10 年平均终身成本（2002 年新台币）分别为肺癌、结直肠癌、肝癌、宫颈癌和乳腺癌 448371 新台币（1 美元≒33 新台币）、584985 新台币、351222 新台币、511563 新台币和 674282 新台币。癌症的总终身成本对于卫生政策制定和临床决策具有重要意义。
